Personalized Medicine for Patients with Respiratory Disease

Dear Colleagues,

The field of respiratory medicine has undergone remarkable advancements over the past few decades, significantly improving the diagnosis, treatment, and management of respiratory diseases. Traditionally, treatments for conditions such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and pulmonary embolism have followed a one-size-fits-all approach. However, the heterogeneity observed in disease progression, response to treatment, and patient outcomes has necessitated a more nuanced approach. The concept of personalized medicine—tailoring medical treatment to the individual characteristics of each patient—has emerged as a transformative strategy in this context. With the advent of high-throughput technologies, advanced imaging, and bioinformatics, we are now equipped to analyze vast amounts of data at an unprecedented scale, paving the way for more precise and effective interventions in respiratory medicine.

This Special Issue on “Personalized Medicine for Patients with Respiratory Diseases” aims to explore the latest developments and innovations in this burgeoning field. Our objective is to provide a comprehensive overview of how personalized medicine is reshaping the landscape of respiratory healthcare. This includes advances in genomics, proteomics, metabolomics, and other omics technologies that are driving the development of personalized therapeutic strategies. We also aim to highlight the integration of clinical data with patient-reported outcomes and real-world evidence to enhance the precision of respiratory disease management. This Special Issue will feature cutting-edge research that showcases the application of personalized medicine to respiratory diseases. Topics of interest include, but are not limited to, the following:

- Genomic and molecular profiling of respiratory diseases.

- Development and validation of biomarkers for early diagnosis and prognosis.

- Personalized therapeutic approaches, including targeted therapies and biologics.

- The role of pharmacogenomics in tailoring drug treatments to individual patients.

- Integration of artificial intelligence and machine learning in personalized respiratory care.

- Case studies demonstrating the successful implementation of personalized treatment plans in clinical practice.

- Ethical, legal, and social implications of personalized medicine in respiratory care.

We invite submissions of original research articles, comprehensive reviews, systematic reviews, meta-analyses, case reports, and perspective pieces that contribute to the understanding and advancement of personalized medicine in respiratory diseases. We are particularly interested in papers that:

- Present novel findings from translational research that bridge the gap between bench and bedside.

- Offer insights into the development of new diagnostic tools and therapeutic interventions.

- Provide evidence from clinical trials or real-world studies on the efficacy and safety of personalized treatments.

- Explore innovative methodologies and technologies for data integration and analysis in personalized respiratory medicine.

- Discuss the policy, ethical, and implementation challenges associated with the adoption of personalized medicine in clinical practice.

This Special Issue aims to serve as a platform for researchers, clinicians, and healthcare professionals to share their latest findings and experiences, fostering collaboration and innovation in the pursuit of personalized healthcare solutions for patients with respiratory diseases. We look forward to receiving your contributions and advancing the field together.

Dr. Foteini Malli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• personalized medicine respiratory diseases
• targeted therapies
• biomarkers
• artificial intelligence
• precision medicine
• diagnostic tools